leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 22:02:19 Page View：6151

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Vertex non
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Wegovy improves function in certain heart failure patients

AdobeJustweeksafterNovoNordiskannouncedthatitsobesitydrugWegovycuttheriskofheartcomplicationsinamajo

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Even great ERs can’t make up for American health disparities

PhotobyScottOlson/GettyImagesFrom“Legacy”byUchéBlackstock,M.D.,publishedbyViking,animprintofPenguinP